Incremental cost effectiveness analysis: DCV/ASV versus PR and PIs considering two prices.
收藏Figshare2015-12-03 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Incremental_cost_effectiveness_analysis_DCV_ASV_versus_PR_and_PIs_considering_two_prices_/1596412
下载链接
链接失效反馈官方服务：
资源简介：
PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, QALY: Quality Adjusted Life Years, ICER: Incremental cost effectiveness ratio, 1 $US = 620 CLP.Incremental cost effectiveness analysis: DCV/ASV versus PR and PIs considering two prices.
创建时间：
2015-12-03
